Game-Changing Diabetes Treatment: Long-Lasting Shots Transforming Care
Stanford engineers have developed a groundbreaking hydrogel drug delivery system that allows GLP-1 drugs, used in the treatment of Type 2 diabetes and weight control, to be administered just three times a year instead of daily or weekly injections. The hydrogel slowly releases the drugs over a four-month period, improving patient compliance and long-term health outcomes. The system has shown promising results in laboratory rats and could potentially be applied to other drugs and conditions. Human clinical trials are expected within the next two years.
